NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024
05 November 2024 - 3:00PM
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American:
NRXS), a medical technology company commercializing neuromodulation
therapies addressing chronic and debilitating conditions in
children and adults, will report summarized financial results for
its third quarter period ended September 30, 2024, on Tuesday,
November 12, 2024, before market open. The Company has scheduled a
conference call for the same day, Tuesday, November 12, 2024, at
9:00 am ET to review the results.
Conference Call Details
Date and Time: Tuesday, November 12, 2024, at
9:00am ET
Live Webcast Information: Interested parties
can access the conference call via a live webcast, which is
available in the Investor Relations section of the Company's
website at https://edge.media-server.com/mmc/p/op4xi3gu or
https://ir.neuraxis.com/. For participants listening through the
webcast, questions can be sent in through the portal using the “Ask
a Question” link or by emailing questions to
NRXS@lythampartners.com.
Call-in Information: Interested parties can
also access the live conference call by initially registering at
the following link.
Upon completion of the registration link, call-in participants
will receive the dial-in info and a unique PIN to join the call as
well as an email confirmation with the details.
Replay: A webcast replay will be available in
the Investor Relations section of the Company's website at
https://edge.media-server.com/mmc/p/op4xi3gu or
https://ir.neuraxis.com/.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on
neuromodulation therapies to address chronic and debilitating
conditions in children and adults. NeurAxis is dedicated to
advancing science and leveraging evidence-based medicine to drive
the adoption of its IB-Stim™ therapy, which is its proprietary
Percutaneous Electrical Nerve Field Stimulation (PENFS) technology,
by the medical, scientific, and patient communities. IB-Stim™ is
FDA-cleared for functional abdominal pain associated with irritable
bowel syndrome (IBS) in adolescents 8-21 years old. Additional
clinical trials of PENFS in multiple pediatric and adult conditions
with large unmet healthcare needs are underway. For more
information, please visit http://neuraxis.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. All statements other than statements of
historical fact are forward-looking statements. Forward-looking
statements are based on management’s current assumptions and
expectations of future events and trends, which affect or may
affect the Company’s business, strategy, operations or financial
performance, and actual results and other events may differ
materially from those expressed or implied in such statements due
to numerous risks and uncertainties. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. There are a number of important factors
that could cause actual results, developments, business decisions
or other events to differ materially from those contemplated by the
forward-looking statements in this press release. These factors
include, among other things, the conditions in the U.S. and global
economy, the trading price and volatility of the Company’s stock,
public health issues or other events, the Company’s compliance with
applicable laws, the results of the Company’s clinical trials and
perceptions thereof, the results of submissions to the FDA, the
results of the shareholder vote to enable the issuance of the
Preferred Stock, and factors described in the Risk Factors section
of NeurAxis’s public filings with the Securities and Exchange
Commission (SEC). Because forward-looking statements are inherently
subject to risks and uncertainties, you should not rely on these
forward-looking statements as predictions of future events. These
forward-looking statements speak only as of the date of this press
release and, except to the extent required by applicable law, the
Company undertakes no obligation to update or revise these
statements, whether as a result of any new information, future
events and developments or otherwise.
For contraindications, precaution, warnings, and IFU, please
see: https://ibstim.com/important-information/.
Contacts:
CompanyNeurAxis,
Inc.info@neuraxis.com
Investor RelationsBen
ShamsianLytham Partners646-829-9701shamsian@lythampartners.com
Neuraxis (AMEX:NRXS)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Neuraxis (AMEX:NRXS)
Historical Stock Chart
Von Dez 2023 bis Dez 2024